Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering

Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an 
Additional Notice of Allowance With Claims Covering RAYOS(R)
(Prednisone) Delayed-Release Tablets 
DEERFIELD, IL -- (Marketwire) -- 02/06/13 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) today announced that Skyepharma has received a Notice
of Allowance from the United States Patent and Trademark Office
(USPTO) for U.S. Patent Application 13/428,548 entitled "Delayed
Release Tablet with Defined Core Geometry" that covers the Company's
U.S. approved product RAYOS(R).  
"This action by the USPTO is another important milestone in expanding
the RAYOS patent estate and demonstrates once again our ongoing
commitment, in partnership with Skyepharma, to protect the innovation
and commercial potential of RAYOS," stated Timothy P. Walbert,
chairman, president and chief executive officer, Horizon Pharma. 
This Notice of Allowance concludes the substantive examination of the
patent application and will result in the issuance of a U.S. patent
after administrative processes are completed. The U.S. patent
scheduled to issue from this application will expire in 2024. After
issuance, Horizon plans to list the U.S. patent in the FDA's Approved
Drug Products with Therapeutic Equivalence Evaluations, or Orange
Book. This will be the third U.S. patent to be listed in the Orange
Book for RAYOS.  
About RAYOS 
 RAYOS, known as LODOTRA(R) in Europe, is a proprietary
delayed-release formulation of low-dose prednisone. The
pharmacokinetic profile of RAYOS is different with an approximately
four-hour lag time from that of immediate-release prednisone
formulations. In clinical trials studying use of RAYOS in rheumatoid
arthritis (RA), patients were administered RAYOS at 10 p.m. with
food. The delayed-release profile of RAYOS helps to achieve
therapeutic prednisone blood levels at a time point when cytokine
levels start rising during the middle of the night. While the
pharmacokinetic profile of RAYOS differs in terms of lag time from
immediate-release prednisone, its absorption, distribution and
elimination processes are comparable. For more information, please
visit www.RAYOSrx.com. 
RAYOS utilizes Skyepharma's proprietary Geoclock(TM) technology.  
Outside the United States, LODOTRA is approved for the treatment of
mo
derate to severe active RA when accompanied by morning stiffness in
19 countries. Horizon has granted commercialization rights for
LODOTRA in Europe, Asia (excluding Japan) and Latin America to its
distribution partner Mundipharma International Corporation Limited.
Horizon has an exclusive license from Skyepharma for RAYOS/LODOTRA. 
Important Safety Information 
RAYOS(R) (prednisone) delayed-release tablets 
Approved uses of RAYOS
 RAYOS, a delayed-release form of prednisone,
prevents the release of substances in the body that cause
inflammation. RAYOS is approved to treat a broad range of diseases
including RA, polymyalgia rheumatica (PMR), psoriatic arthritis
(PsA), ankylosing spondylitis (AS), asthma and chronic obstructive
pulmonary disease (COPD). For a full list of RAYOS indications,
please see full prescribing information at www.RAYOSrx.com. 
RAYOS is contraindicated in patients who have known hypersensitivity
to prednisone or to any of the excipients. Rare instances of
anaphylaxis have occurred in patients receiving corticosteroids. 
Important information about RAYOS 
 Do not use RAYOS if you are
allergic to prednisone. 
Long-term use of RAYOS can affect how your body responds to stress.
Symptoms can include weight gain, severe fatigue, weak muscles and
high blood sugar. 
RAYOS can weaken your immune system, making it easier for you to get
an infection or worsening an infection you already have or have
recently had. 
RAYOS can cause high blood pressure, salt and water retention and low
blood potassium. 
There is an increased risk of developing holes in the stomach or
intestines if you have certain stomach and intestinal disorders. 
Behavior and mood changes can occur, including intense excitement or
happiness, sleeplessness, mood swings, personality changes or severe
depression. 
Long-term use of RAYOS can cause decreases in bone density. 
RAYOS can cause cataracts, eye infections and glaucoma. 
Do not receive a "live" vaccine while taking RAYOS. The vaccine may
not work as well during this time and may not fully protect you from
disease. 
Taking RAYOS during the first trimester of pregnancy can harm an
unborn baby. 
Long-term use of RAYOS can slow growth and development in children. 
The most common side effects with RAYOS are water retention, high
blood sugar, high blood pressure, unusual behavior and mood changes,
increased appetite and weight gain. 
Please
 see full prescribing information for RAYOS at www.RAYOSrx.com. 
About Horizon Pharma
 Horizon Pharma, Inc. is a specialty
pharmaceutical company that has developed and is commercializing
DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic
needs in arthritis, pain and inflammatory diseases. The Company's
strategy is to develop, acquire, in-license and/or co-promote
additional innovative medicines where it can execute a targeted
commercial approach in specific therapeutic areas while taking
advantage of its commercial strengths and the infrastructure the
Company has put in place. 
About Skyepharma PLC
 Skyepharma uses its multiple drug delivery
technologies and expertise to create pharmaceutical products. The
Group receives revenues from 13 approved products in the areas of
inhalation, oral, topical and injectable delivery as well as
generating income from the development of further products and
technology licenses. The Group's products are marketed throughout the
world by leading pharmaceutical companies. For more information,
visit www.Skyepharma.com. 
Forward-Looking Statements
 This press release contains
forward-looking statements, including statements regarding the
issuance of a patent based on the notice of allowance from the U.S.
Patent and Trademark Office and the ability to protect the innovation
and commercial potential of RAYOS. These forward-looking statements
are based o
n management's expectations and assumptions as of the date
of this press release, and actual results may differ materially from
those in these forward-looking statements as a result of various
factors. These factors include risks regarding whether the
administrative processes required for the issuance of a patent as
indicated in the notice of allowance will be completed in a timely
matter or at all, whether the patent, if issued as indicated in the
notice of allowance, will provide sufficient protection and market
exclusivity for RAYOS, whether any patents issued to Horizon may be
challenged, invalidated, infringed or circumvented by third parties
and other factors described in Horizon's filings with the United
States Securities and Exchange Commission, including those factors
discussed under the caption "Risk Factors" in those filings.
Forward-looking statements speak only as of the date of this press
release, and Horizon undertakes no obligation to update or revise
these statements, except as may be required by law.  
Contacts
Robert J. De Vaere
Executive Vice President, Chief Financial Officer
investor-relations@horizonpharma.com 
Investors
Kathy Galante
Burns McClellan, Inc.
kgalante@burnsmc.com
212-213-0006